Collaboration extends world-wide access for Thermo Fisher’s fast subsequent-technology sequencing technologies
Meeting connect with to be held right now at 4:30 pm ET/1:30 pm PT
IRVINE, Calif., Jan. 18, 2022 (World NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics organization with the mission to enhance affected person results by furnishing obvious insights that tell crucial decisions in the prognosis, cure, and monitoring of most cancers, today declared a progress and co-internet marketing agreement for two dispersed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s Ion Torrent™ Genexus™ Method.* The settlement also grants Oncocyte rights to produce foreseeable